AgingResearch.NewsJoin free

Jak/stat3 inhibitor

Intervention

1 paper1 finding

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: Japan Society for the Promotion of Science and 3 more
  • Animals1

Outcomes

1

Peritoneal dissemination of gastric cancer

downin mice1

1 study

  1. Jak/stat3 inhibitor decreases peritoneal dissemination of gastric cancer in mice.

    “A JAK/STAT3 inhibitor blocks the increase in GC cell viability induced by senescent CAFs and peritoneal tumor formation.”

    Animalsinduced by senescent CAFs

    Inflammation-driven senescence-associated secretory phenotype in cancer-associated fibroblasts enhances peritoneal dissemination

    Cell reports23 Feb 2021

More on Peritoneal dissemination of gastric cancer

Latest

Related